 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

As per the report by Visiongain, the Rare Diseases Market was valued at US$188.58 billion in 2022 and is projected to grow at a CAGR of 12.27% during the forecast period 2023-2033. Visiongain has published a new report entitledRare Diseases2023-2033. It includes profiles of Rare Diseases and ...

Rare Diseases Market is projected to grow at a CAGR of 12.27% by 2033: Visiongain

Visiongain has published a new report entitledRare Diseases2023-2033. It includes profiles of Rare Diseases and Forecasts Market Segment by Diseases (Cancer, Metabolic Diseases, Neurological Conditions, Hematologic Disorders, Infectious Diseases, Musculoskeletal Disorders, Cardiovascular Disorders, ...

Rare Diseases Market is projected to grow at a CAGR of 12.27% by 2033: Visiongain Reports Ltd

Visiongain has published a new report entitled Rare Diseases 2023-2033. It includes profiles of Rare Diseases and Forecasts Market Segment by Diseases (Cancer, Metabolic Diseases, Neurological Conditions, Hematologic Disorders, Infectious Diseases, Musculoskeletal Disorders, Cardiovascular Disorders...

Alexion, AstraZeneca Rare Disease, today announced the completion of its acquisition of LogicBio Therapeutics, Inc. (NASDAQ: LOGC), a pioneering genomic medicine company. The acquisition creates an opportunity to accelerate Alexions growth in genomic medicines through unique technology, an...

Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio Therapeutics

Dr James Fox explores whether AstraZeneca shares are right for his portfolio after two years of strong share-price growth.
The post If Id invested 500 in AstraZeneca shares 2 years ago, heres how much Id have now! appeared first on The Motley Fool UK.

AstraZeneca (LSE:AZN) ...

If I'd invested GBP500 in AstraZeneca shares 2 years ago, here's how much I'd have now!

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BTRS, JVA, AKUS, LOGC SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BTRS, JVA, AKUS, LOGC PR Newswire NEW YORK, Oct. 31, 2022 NEW YORK, Oct. 31, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BTRS, JVA, AKUS, LOGC

LogicBio Therapeutics (NASDAQ:LOGC  Get Rating) and Aziyo Biologics (NASDAQ:AZYO  Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, analyst ...

LogicBio Therapeutics (NASDAQ:LOGC) & Aziyo Biologics (NASDAQ:AZYO) Head-To-Head Review

NEW YORK, Oct. 23, 2022 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Southern Missouri Bancorp, Inc. (NASDAQ: SMBC)s...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SMBC, BTRS, LOGC, RCOR

SHAREHOLDER ALERT: Weiss Law Reminds LOGC, POSH, AERC, and BTRS Shareholders About Its Ongoing Investigations SHAREHOLDER ALERT: Weiss Law Reminds LOGC, POSH, AERC, and BTRS Shareholders About Its Ongoing Investigations PR Newswire NEW YORK, Oct. 20, 2022 NEW YORK, Oct. 20, 2022 /PRNewswire/ -- If...

SHAREHOLDER ALERT: Weiss Law Reminds LOGC, POSH, AERC, and BTRS Shareholders About Its Ongoing Investigations

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AAWW, LOGC, RFP, PBFX, RNWK SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AAWW, LOGC, RFP, PBFX, RNWK PR Newswire NEW YORK, Oct. 18, 2022 NEW YORK, Oct. 18, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AAWW, LOGC, RFP, PBFX, RNWK

LogicBio develops gene therapy vectors for previously incurable genetic and infectious diseases. It is committed to delivering genetic medicine to pediatric patients with rare diseases. Their proprietary technology based on the non-pathogenic adeno-associated viral vector offers superior efficiency and safety compared to all competitors on the market and is uniquely suited for the treatment of children as well as adults.

Watchers	735
52-Wk Low	$0.2573
52-Wk High	$3.53

Market Cap	$68.23M
Volume (M)	153,044.00
52-Wk High	$3.53
52-Wk Low	$0.2573

Current Price	$2.07
Prev Close	$2.06
Open	$2.06
Dividend Yield	N/A
50-Day Moving Average	$1.47
Beta	1.62
Avg. Volume	1.23M
PE Ratio	-2.57

52-Week High	$3.53
52-Week Low	$0.2573
Market Capitalization	$68.23M
EPS	-$0.8054
Price to Book	4.34
Revenue Per Employee	N/A
Enterprise Value/EBITDA	0.49

LOGC LogicBio Therapeutics Inc

About

Feed

News

Fundamentals